In the latest quarter, 17 analysts provided ratings for Boston Scientific BSX, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 9 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 4 | 5 | 1 | 0 | 0 |
| 3M Ago | 3 | 3 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.24, with a high estimate of $80.00 and a low estimate of $62.00. This upward trend is apparent, with the current average reflecting a 10.78% increase from the previous average price target of $62.50.
Analyzing Analyst Ratings: A Detailed Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Boston Scientific. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joshua Jennings | TD Cowen | Raises | Outperform | $77.00 | $65.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $70.00 | - |
| Joanne Wuensch | Citigroup | Raises | Buy | $71.00 | $65.00 |
| Mike Matson | Needham | Raises | Buy | $71.00 | $60.00 |
| Jayson Bedford | Raymond James | Raises | Strong Buy | $73.00 | $67.00 |
| Steven Lichtman | Oppenheimer | Raises | Perform | $68.00 | $58.00 |
| Anthony Petrone | Mizuho | Announces | Buy | $80.00 | - |
| Shagun Singh | RBC Capital | Raises | Outperform | $70.00 | $67.00 |
| Robbie Marcus | JP Morgan | Raises | Overweight | $72.00 | $60.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $72.00 | $70.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $67.00 | - |
| Jayson Bedford | Raymond James | Raises | Strong Buy | $67.00 | $61.00 |
| Marie Thibault | BTIG | Maintains | Buy | $64.00 | $64.00 |
| Larry Biegelsen | Wells Fargo | Maintains | Overweight | $62.00 | $62.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $66.00 | $59.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $62.00 | $59.00 |
| Joshua Jennings | TD Cowen | Raises | Outperform | $65.00 | $58.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Scientific compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Boston Scientific's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Capture valuable insights into Boston Scientific's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
Discovering Boston Scientific: A Closer Look
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Boston Scientific's Financial Performance
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Boston Scientific's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.9% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Boston Scientific's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Boston Scientific's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.65%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Boston Scientific's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.46%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average at 0.49, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
